Company Overview - Shenzhen Kaili Biomedical Technology Co., Ltd. specializes in the independent research, development, production, and sales of medical diagnostic and treatment equipment, including ultrasound diagnostic devices, endoscopes, minimally invasive surgical products, and cardiovascular intervention products [2] - The company has developed HD-500 and HD-550 series high-definition endoscopes, which are widely recognized by clinical doctors and represent the leading level of domestic endoscopes [2] - Kaili Medical is one of the earliest companies in China to develop and master core technologies for color Doppler ultrasound equipment and probes, maintaining a leading position in the domestic industry [2] Market Position - As of the latest report, Kaili Medical's stock price closed at 30.4 yuan, with a rolling price-to-earnings (PE) ratio of 54.18 times, and a total market capitalization of 13.154 billion yuan [1] - The average PE ratio in the medical device industry is 46.46 times, with a median of 33.07 times, placing Kaili Medical at the 93rd position in the industry ranking [1][3] Financial Performance - For the third quarter of 2024, the company reported revenue of 1.398 billion yuan, a year-on-year decrease of 4.74%, and a net profit of 109 million yuan, down 66.01% year-on-year [3] - The gross profit margin for the company stands at 66.59% [3] Institutional Holdings - As of the third quarter of 2024, a total of 331 institutions hold shares in Kaili Medical, including 330 funds and 1 brokerage, with a total shareholding of 95.8485 million shares valued at 2.817 billion yuan [1]